development: be very profitable for pharmaceutical companies

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents concept
Weight: 0.63
, aspect
Weight: 0.60
, step
Weight: 0.60
, process
Weight: 0.60
Siblings acquisition
Weight: 0.69
, artificial intelligence
Weight: 0.64
, discovery
Weight: 0.62
, well
Weight: 0.60
, cell division
Weight: 0.60

Related properties

Property Similarity
be very profitable for pharmaceutical companies 1.00
be very profitable for companies 0.93
be important to company 0.81
have popular in many firms competing in global economy strategies 0.81
have popular in firms competing in global economy strategies 0.80
be important in business 0.79
be important to business 0.78

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Plausibility inference from child typicality

0.49
Rule weight: 0.66
Evidence weight: 0.94
Similarity weight: 0.79
Evidence: 0.94
Plausible(process, be important in business) ⋁
Evidence: 0.96
¬ Typical(development, be very profitable for pharmaceutical companies)
0.42
Rule weight: 0.66
Evidence weight: 0.81
Similarity weight: 0.78
Evidence: 0.80
Plausible(aspect, be important to business) ⋁
Evidence: 0.96
¬ Typical(development, be very profitable for pharmaceutical companies)

Plausibility inheritance from parent to child

0.07
Rule weight: 0.09
Evidence weight: 0.94
Similarity weight: 0.78
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.80
¬ Plausible(aspect, be important to business)
0.07
Rule weight: 0.09
Evidence weight: 0.93
Similarity weight: 0.79
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.94
¬ Plausible(process, be important in business)

Remarkability exclusitivity betweem a parent and a child

0.29
Rule weight: 0.58
Evidence weight: 0.64
Similarity weight: 0.78
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.54
¬ Remarkable(aspect, be important to business)
0.25
Rule weight: 0.58
Evidence weight: 0.56
Similarity weight: 0.79
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.66
¬ Remarkable(process, be important in business)

Remarkability exclusitivity between siblings

0.07
Rule weight: 0.13
Evidence weight: 0.61
Similarity weight: 0.81
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.58
¬ Remarkable(acquisition, have popular in many firms competing in global economy strategies)
0.07
Rule weight: 0.13
Evidence weight: 0.61
Similarity weight: 0.80
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.58
¬ Remarkable(acquisition, have popular in firms competing in global economy strategies)

Remarkability from parent implausibility

0.32
Rule weight: 0.42
Evidence weight: 0.98
Similarity weight: 0.79
Evidence: 0.94
Plausible(process, be important in business) ⋁
Evidence: 0.66
Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.93
¬ Plausible(development, be very profitable for pharmaceutical companies)
0.31
Rule weight: 0.42
Evidence weight: 0.94
Similarity weight: 0.78
Evidence: 0.80
Plausible(aspect, be important to business) ⋁
Evidence: 0.66
Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.93
¬ Plausible(development, be very profitable for pharmaceutical companies)

Remarkability from sibling implausibility

0.47
Rule weight: 0.60
Evidence weight: 0.97
Similarity weight: 0.81
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.58
Remarkable(acquisition, have popular in many firms competing in global economy strategies) ⋁
Evidence: 0.97
¬ Plausible(acquisition, have popular in many firms competing in global economy strategies)
0.47
Rule weight: 0.60
Evidence weight: 0.97
Similarity weight: 0.80
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.58
Remarkable(acquisition, have popular in firms competing in global economy strategies) ⋁
Evidence: 0.97
¬ Plausible(acquisition, have popular in firms competing in global economy strategies)

Salient implies Plausible

0.26
Rule weight: 0.28
Evidence weight: 0.93
Similarity weight: 1.00
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.98
¬ Salient(development, be very profitable for pharmaceutical companies)

Similarity expansion

0.68
Rule weight: 0.85
Evidence weight: 0.98
Similarity weight: 0.81
Evidence: 0.98
Salient(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.87
¬ Salient(development, be important to company)
0.67
Rule weight: 0.85
Evidence weight: 0.98
Similarity weight: 0.81
Evidence: 0.96
Typical(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.62
¬ Typical(development, be important to company)
0.66
Rule weight: 0.85
Evidence weight: 0.95
Similarity weight: 0.81
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.70
¬ Plausible(development, be important to company)
0.49
Rule weight: 0.85
Evidence weight: 0.72
Similarity weight: 0.81
Evidence: 0.66
Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.84
¬ Remarkable(development, be important to company)

Typical and Remarkable implies Salient

0.14
Rule weight: 0.14
Evidence weight: 0.99
Similarity weight: 1.00
Evidence: 0.98
Salient(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.96
¬ Typical(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies)

Typical implies Plausible

0.45
Rule weight: 0.48
Evidence weight: 0.93
Similarity weight: 1.00
Evidence: 0.93
Plausible(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.96
¬ Typical(development, be very profitable for pharmaceutical companies)

Typicality and Rermarkability incompatibility between a parent and a child

0.17
Rule weight: 0.51
Evidence weight: 0.43
Similarity weight: 0.78
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.86
¬ Typical(aspect, be important to business)
0.14
Rule weight: 0.51
Evidence weight: 0.35
Similarity weight: 0.79
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.97
¬ Typical(process, be important in business)

Typicality and Rermarkability incompatibility between siblings

0.04
Rule weight: 0.14
Evidence weight: 0.34
Similarity weight: 0.81
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 1.00
¬ Typical(acquisition, have popular in many firms competing in global economy strategies)
0.04
Rule weight: 0.14
Evidence weight: 0.34
Similarity weight: 0.80
Evidence: 0.66
¬ Remarkable(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 1.00
¬ Typical(acquisition, have popular in firms competing in global economy strategies)

Typicality inheritance from parent to child

0.37
Rule weight: 0.48
Evidence weight: 0.96
Similarity weight: 0.79
Evidence: 0.96
Typical(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.97
¬ Typical(process, be important in business)
0.37
Rule weight: 0.48
Evidence weight: 0.97
Similarity weight: 0.78
Evidence: 0.96
Typical(development, be very profitable for pharmaceutical companies) ⋁
Evidence: 0.86
¬ Typical(aspect, be important to business)